Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

17

Other

7

Investigational

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cyclooxygenase

12

Copper

5

Carbonic anhydrase IV

2

Carbonic anhydrase VA

2

Carbonic anhydrase VB

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

17

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1974

12

Unknown

9

1985

5

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Backache

12

Common cold

12

Headache

12

Muscular aches

12

Toothache

12

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

12

Preventing

5

Primary

5

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

17

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Adams, S. at Boots Pure Drug

12

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

26

All Match

Any Match

Exclude Selected

Exclude Selected

INN Stem

Chemical substance(-ine)

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

26

FDA UNII

26

PUBCHEM

26

EPA CompTox

21

ECHA (EC/EINECS)

16

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

1

CARDIOVASCULAR SYSTEM

1

GENITO URINARY SYSTEM AND SEX HORMONES

1

MUSCULO-SKELETAL SYSTEM

1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANALGESICS

1

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

1

CARDIAC THERAPY

1

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

1

OTHER GYNECOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

1

OPIOIDS

1

OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

1

OTHER CARDIAC PREPARATIONS

1

OTHER GYNECOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antiinflammatory preparations, non-steroids for topical use

1

Antiinflammatory products for vaginal administration

1

Opioids in combination with non-opioid analgesics

1

Other cardiac preparations

1

Other throat preparations

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

21

Principal Form

5

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 26 results

First page disabled
Previous page disabled
1
Next page
Next page

Trientine

SJ76Y07H5F

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 1985

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Wilson's disease

Trientine, also known as triethylenetatramine or abbreviation TETA, is a highly selective divalent Cu(II) chelator and orphan drug that reverses copper overload in tissues. It was approved as second-line pharmacotherapy for Wilson's disease. Wilson's...

disease (hepatolenticular degeneration) is an autosomal inherited metabolic defect resulting in an inability to maintain a near-zero balance of copper. Excess copper accumulates possibly because the liver lacks the mechanism to excrete free copper into the bile. Hepatocytes store excess copper but when their capacity is exceeded copper is released into the blood and is taken up into extrahepatic sites. This condition is treated with a low copper diet and the use of chelating agents that bind copper to facilitate its excretion from the body. Although penicillamine treatment is believed to be more extensive, TETA therapy has been shown to be an effective initial therapy. In addition, TETA is in a clinical trial phase II for the prevention of the Macular Edema after Cataract Surgery. TETA is also considered a potential chemotherapeutic agent as it could be a telomerase inhibitor. Chelating excess copper may affect copper-induced angiogenesis. Other mechanisms of action of TETA for alternative therapeutic implications include improved antioxidant defense against oxidative stress, pro-apoptosis, and reduced inflammation.

IBUPROFEN

WK2XYI10QM

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1974

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Conditions:

Ibuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-inflammatory drug (NSAID), with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, which are though...

t to act through inhibition of prostaglandin synthesis. It’s used temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps and temporarily reduces fever. The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more pharmacologically active enantiomer.

SPERMINE

2FZ7Y3VOQX

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Carbonic anhydrase IV

Carbonic anhydrase VII

Glutamate NMDA receptor

Carbonic anhydrase VB

Carbonic anhydrase VA

HEXAMETHYLENEDIAMINE

ZRA5J5B2QW

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

N,N-BIS(3-AMINOPROPYL)METHYLAMINE

62ZM34D74O

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

TRIENTINE TETRAACETATE

NZG941KW51

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 1985

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Wilson's disease

Trientine, also known as triethylenetatramine or abbreviation TETA, is a highly selective divalent Cu(II) chelator and orphan drug that reverses copper overload in tissues. It was approved as second-line pharmacotherapy for Wilson's disease. Wilson's...

disease (hepatolenticular degeneration) is an autosomal inherited metabolic defect resulting in an inability to maintain a near-zero balance of copper. Excess copper accumulates possibly because the liver lacks the mechanism to excrete free copper into the bile. Hepatocytes store excess copper but when their capacity is exceeded copper is released into the blood and is taken up into extrahepatic sites. This condition is treated with a low copper diet and the use of chelating agents that bind copper to facilitate its excretion from the body. Although penicillamine treatment is believed to be more extensive, TETA therapy has been shown to be an effective initial therapy. In addition, TETA is in a clinical trial phase II for the prevention of the Macular Edema after Cataract Surgery. TETA is also considered a potential chemotherapeutic agent as it could be a telomerase inhibitor. Chelating excess copper may affect copper-induced angiogenesis. Other mechanisms of action of TETA for alternative therapeutic implications include improved antioxidant defense against oxidative stress, pro-apoptosis, and reduced inflammation.

TRIENTINE ACETATE

48P82SYS6Z

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 1985

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Wilson's disease

Trientine, also known as triethylenetatramine or abbreviation TETA, is a highly selective divalent Cu(II) chelator and orphan drug that reverses copper overload in tissues. It was approved as second-line pharmacotherapy for Wilson's disease. Wilson's...

disease (hepatolenticular degeneration) is an autosomal inherited metabolic defect resulting in an inability to maintain a near-zero balance of copper. Excess copper accumulates possibly because the liver lacks the mechanism to excrete free copper into the bile. Hepatocytes store excess copper but when their capacity is exceeded copper is released into the blood and is taken up into extrahepatic sites. This condition is treated with a low copper diet and the use of chelating agents that bind copper to facilitate its excretion from the body. Although penicillamine treatment is believed to be more extensive, TETA therapy has been shown to be an effective initial therapy. In addition, TETA is in a clinical trial phase II for the prevention of the Macular Edema after Cataract Surgery. TETA is also considered a potential chemotherapeutic agent as it could be a telomerase inhibitor. Chelating excess copper may affect copper-induced angiogenesis. Other mechanisms of action of TETA for alternative therapeutic implications include improved antioxidant defense against oxidative stress, pro-apoptosis, and reduced inflammation.

TRIENTINE TETRAHYDROCHLORIDE

7360URE56Q

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 1985

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Wilson's disease

Trientine, also known as triethylenetatramine or abbreviation TETA, is a highly selective divalent Cu(II) chelator and orphan drug that reverses copper overload in tissues. It was approved as second-line pharmacotherapy for Wilson's disease. Wilson's...

disease (hepatolenticular degeneration) is an autosomal inherited metabolic defect resulting in an inability to maintain a near-zero balance of copper. Excess copper accumulates possibly because the liver lacks the mechanism to excrete free copper into the bile. Hepatocytes store excess copper but when their capacity is exceeded copper is released into the blood and is taken up into extrahepatic sites. This condition is treated with a low copper diet and the use of chelating agents that bind copper to facilitate its excretion from the body. Although penicillamine treatment is believed to be more extensive, TETA therapy has been shown to be an effective initial therapy. In addition, TETA is in a clinical trial phase II for the prevention of the Macular Edema after Cataract Surgery. TETA is also considered a potential chemotherapeutic agent as it could be a telomerase inhibitor. Chelating excess copper may affect copper-induced angiogenesis. Other mechanisms of action of TETA for alternative therapeutic implications include improved antioxidant defense against oxidative stress, pro-apoptosis, and reduced inflammation.

TRIENTINE HYDROCHLORIDE

HC3NX54582

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 1985

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Wilson's disease

Trientine, also known as triethylenetatramine or abbreviation TETA, is a highly selective divalent Cu(II) chelator and orphan drug that reverses copper overload in tissues. It was approved as second-line pharmacotherapy for Wilson's disease. Wilson's...

disease (hepatolenticular degeneration) is an autosomal inherited metabolic defect resulting in an inability to maintain a near-zero balance of copper. Excess copper accumulates possibly because the liver lacks the mechanism to excrete free copper into the bile. Hepatocytes store excess copper but when their capacity is exceeded copper is released into the blood and is taken up into extrahepatic sites. This condition is treated with a low copper diet and the use of chelating agents that bind copper to facilitate its excretion from the body. Although penicillamine treatment is believed to be more extensive, TETA therapy has been shown to be an effective initial therapy. In addition, TETA is in a clinical trial phase II for the prevention of the Macular Edema after Cataract Surgery. TETA is also considered a potential chemotherapeutic agent as it could be a telomerase inhibitor. Chelating excess copper may affect copper-induced angiogenesis. Other mechanisms of action of TETA for alternative therapeutic implications include improved antioxidant defense against oxidative stress, pro-apoptosis, and reduced inflammation.

IBUPROFEN DL-LYSINE

079X7DL13M

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 1974

Class (Stereo):

CHEMICAL (MIXED)

Targets:

Conditions:

Ibuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-inflammatory drug (NSAID), with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, which are though...

t to act through inhibition of prostaglandin synthesis. It’s used temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps and temporarily reduces fever. The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more pharmacologically active enantiomer.

Showing 1 - 10 of 26 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1